C-RAD Is Selected At 3 U.S. Proton Cancer Treatment Centers

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

December 28, 2020

C-Rad offers a specific version of its Catalyst™ System for use in proton and particle therapy – Catalyst PT. It is based on the patented Catalyst technology and software as well as the hardware is tailored for the application in this environment.

The Catalyst system is delivered with the complete software suite with modules for Respiratory Gating, Patient Setup and Positioning, and Motion Monitoring. The C-RAD SIGRT solution provides continuous monitoring of the patient during a treatment fraction. The system is delivered with interfaces that allow to interrupt the treatment beam if patient motion is above a clinically defined threshold.

C-RAD Sentinel 4DCT™ is an easy-to-use, laser-based optical surface scanning system with functionality for four-dimensional CT image reconstruction and gated imaging in a CT room.

“There is a trend within radiation therapy towards high precision treatments. The goal is to improve treatment success and at the same time spare the healthy tissue to minimize side effects.” continues Tim Thurn, “To the benefit of the patient, there is a strong motivation to reduce the time for patient setup and positioning. The C-RAD solution is made to support such treatments in a safer and more efficient way.”

The total order has a value of 15 MSEK for C-RAD. Delivery and installation for the first center are expected to be concluded during the next three months. The other sites will follow in 2021 and 2022.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.